Caplin Point Laboratories has announced a board meeting scheduled for November 05, 2025, to review and approve the unaudited financial results for the quarter and half-year ended September 30, 2025. The results will be considered on both a standalone and consolidated basis. This update was communicated to the stock exchanges on October 29, 2025.
Board Meeting Announcement
Caplin Point Laboratories will hold a meeting of its Board of Directors on November 05, 2025. The primary purpose of this meeting is to discuss and approve the company’s financial performance.
Financial Results on the Agenda
The board will review and approve the unaudited financial results for Q2 FY26, specifically the quarter and half-year which ended on September 30, 2025. These results will be analyzed on both a standalone and consolidated basis, offering a comprehensive view of the company’s financial standing.
Trading Window Closure
As previously communicated on September 29, 2025, the trading window for designated persons and their immediate relatives remains closed from October 01, 2025, and will remain closed until November 07, 2025. This restriction aligns with the company’s code of conduct for regulating insider trading.
Source: BSE
